Nobel medicine prize goes to 3 scientists for research into brain activity

US psychiatrist and neurologist Karl Deisseroth, together with German researchers Peter Hegemann and Georg Nagel, have been awarded the 2023 Nobel Prize in Physiology or Medicine for pioneering the field of optogenetics, a technique that uses light‑sensitive proteins to control neuronal activity. Their work, which began with Hegemann and Nagel’s early‑2000s discovery of the algal protein channelrhodopsin and Deisseroth’s adaptation of that protein to switch nerve cells on and off in mouse brains, has opened a new era in neuroscience by allowing scientists to toggle specific neural circuits that underlie memories, emotions and behaviours linked to neurological and psychiatric disorders. The Nobel Assembly praised the trio for “revealing how to switch on and off neural circuits behind specific memories, feelings, and behaviours,” noting that the method has already been applied in clinical trials aimed at restoring sight in patients with retinitis pigmentosa, and the laureates will share the 900,000‑pound prize money.

The significance of optogenetics lies in its ability to illuminate previously opaque aspects of brain function, providing a precise tool to dissect how individual neurons and pathways contribute to complex mental processes and disease states. By inserting channelrhodopsin into targeted cells, researchers can activate or silence them with millisecond precision using light, enabling experiments that directly link neural activity to behavioural outcomes. This capability has already yielded insights into the nervous system’s interaction with peripheral organs such as the heart and gut, and has propelled a wave of discoveries that deepen our understanding of the biological basis of cognition and emotion. Moreover, the technique’s translational potential is evident in ongoing efforts to treat visual impairment, where patients receive a gene‑therapy‑delivered light‑responsive protein and regain partial vision when exposed to specialized glasses that emit activating light.

The broader impact of the Nobel‑winning research is already reshaping both basic science and therapeutic development. Laboratories worldwide are now employing optogenetic tools to map neural circuits implicated in conditions ranging from depression to epilepsy, accelerating the search for targeted interventions. Clinical trials building on the vision‑restoration approach suggest a pathway toward gene‑based, light‑driven therapies for a variety of sensory and neurological disorders. As the Nobel Committee highlighted, each day brings new discoveries that bring humanity closer to solving the profound mystery of how the brain works, and the laureates’ breakthrough continues to inspire collaborations that could translate precise neural control into real‑world medical solutions.

⚡ Effects Interpreter